Cybrexa Therapeutics
Vishwas Paralkar has a strong background in scientific research and development. Vishwas joined Modifi Bio in 2022 as a Member of the Scientific Advisory Board. Before that, they worked at Cybrexa Therapeutics starting from 2017, where they held the position of Chief Scientific Officer. From 2010 to 2017, Vishwas served as the Chief Scientific Officer at Karos Pharmaceuticals. Prior to that, they had a long tenure at Pfizer Pharmaceuticals, starting in 1995. During their time at Pfizer, they held various roles including Director and Associate Research Fellow. Vishwas also worked as a Senior Research Scientist at SVP Pfizer from 1995 to 1998. Vishwas began their career as a Research Fellow at the National Institute for Medical Research in 1989.
Vishwas Paralkar pursued their education from 1984 to 1989 at Howard University, where they obtained a Ph.D. in Cell Biology/Biochemistry.
Cybrexa Therapeutics
1 followers
Cybrexa Therapeutics is developing an entirely new class of small molecule DNA repair inhibitors that directly target the tumor microenvironment. This approach leverages a novel tumor-localizing peptide technology developed by an internationally recognized research laboratory at Yale. Our approach will change the paradigm of drug delivery, and itwill greatly enhance the therapeutic index. It has the potential to re-define the definition of “drug-like,” which will unlock a vast array of molecules for clinical development. Our collection of tumor-localizing DNA repair inhibitors can be combined with numerous chemotherapies and also radiotherapy, allowing the safe delivery of higher drug doses, with enhanced efficacy.